Lotilaner
Lotilaner, sold under the brand name Xdemvy, is an ectoparasiticide medication used for the treatment of blepharitis caused by infestation by Demodex. It is used as an eye drop.
It was approved for medical use in the United States in July 2023. The US Food and Drug Administration considers it to be a first-in-class medication.
Lotilaner is a member of the isoxazoline family of compounds.
Medical uses
Lotilaner is indicated for the treatment of Demodex blepharitis. It had been first used in veterinary medicine against fleas and ticks, and later for Demodex mites.Veterinary uses
Lotilaner, sold under the brand name Credelio among others, is a veterinary medication used to control fleas and ticks in dogs and cats. It is indicated for the treatment and prevention of flea infestations and for the treatment and control of tick infestations including lone star tick, American dog tick '', black-legged tick, and brown dog tick. It is taken by mouth.Lotilaner in combination with milbemycin oxime is sold under the brand name Credelio Plus. It is used in dogs to treat concurrent infestations with parasites living outside and inside the animal's body.
Lotilaner is used for the treatment of flea, tick, and mite infestations in dogs, including treatment of demodicosis.
Mechanism of action
Lotilaner paralyzes and kills parasites by interfering with the way that signals are passed between their nerve cells.Lotilaner is a gamma-aminobutyric acid -gated chloride channel inhibitor selective for arthropods. Inhibition of these GABA chloride channels causes a paralytic action in the target organism leading to its death. Lotilaner is not an inhibitor of mammalian GABA mediated chloride channels when tested at up to 30 µM in vitro.